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Enhancing the Development and Approval of Acute
Stroke Therapies
Stroke Therapy Academic Industry Roundtable
Marc Fisher, MD; for the Stroke Therapy Academic Industry Roundtable IV
Background—Previous Stroke Therapy Academic Industry Roundtable (STAIR) meetings focused on preclinical evidence
of drug efficacy and enhancing acute stroke trial design and performance. A fourth (STAIR-IV) was held to discuss
relevant issues related to acute stroke drug development and regulatory approval.
Summary of Review—The STAIR-IV meeting had 3 main focus areas. The first topic was novel approaches to statistical
design of acute stroke trials and appropriate outcome measures. The second focus was the need for better cooperation
among participants in stroke therapy development that may be addressed through a national consortium of stroke trial
centers in the United States and elsewhere. Lastly, regulatory issues related to the approval of novel mono and multiple
acute stroke therapies were discussed.
Conclusions—The development of additional acute stroke therapies represents a large unmet need with many remaining
challenges and also opportunities to incorporate novel approaches to clinical trial design that will lead to regulatory
approval. The STAIR-IV meeting explored new concepts of trial methodology and data analysis, initiatives for
implementing a US clinical trialist consortium, and pertinent regulatory issues to expedite approval of novel therapies.
(Stroke. 2005;36:1808-1813.)
Key Words: ischemia  stroke, acute
The historic failure of neuroprotective ischemic stroketrials and the slow progress in the development of
reperfusion drugs and techniques continue to stimulate debate
focused on clinical trial design. This report builds on the
discussions of the 3 previous STAIR conferences and focuses
on further considerations related to clinical trial design and
outcome assessment of treatment effects, on enhancement of
cooperation among stroke trial participants, and on regulatory
aspects related to the development of acute stroke thera-
pies.1–3 The unique requirements of device trials will be the
topic of a future STAIR conference.
Recommendations for Improving Clinical
Trial Design and Outcome Assessment
Several of the important issues concerning phase II and III
trials that were addressed in STAIR-II need to be reconsid-
ered in view of recent advances in the field.2 These include
pharmacokinetic evaluation and characterization of the dose
response, the need to demonstrate adequate brain penetration
of the drug being evaluated, enhancement of patient selection
for phase II and III trials, and improvement of outcome
assessment.
Phase III studies continue to be conducted despite limited
pharmacokinetic data from animal and preliminary human stud-
ies. Helpful pharmacological data include the following: effec-
tive plasma levels, time window, and the delineation of a ED95
(the minimal dose that achieves 95% of the maximal effect) of
a drug. A previous STAIR meeting emphasized that lack of
establishing the optimal dose, duration of therapy, and time
window may have contributed to the failure of neuroprotection
trials.2 Better characterization of dose-response relationships and
the determination of the optimal dose to be used in phase III
trials should improve the chances for demonstrating efficacy.
The use of an adaptive design with real-time learning of the
dose-response relationship of a drug and continuous reassess-
ment of futility could enhance the efficiency of phase IIB
trials.4,5 This approach was successfully used in the Acute Stroke
Therapy by Inhibition of Neutrophils (ASTIN) trial and led to
early termination of the study because of futility.6 As compared
with a traditional design where a fixed number of patients are
allocated to a small number of doses,2–3 a larger number of
treatment arms6–16 are used in a sequential design in which a
Bayesian algorithm continuously models the dose-response on
the basis of all outcome data collected across all treatment arms.
Treatment allocation is adaptive in that the system is designed to
optimize the integration of the dose-response data and the
determination of the ED95. Adaptive-design trials are associated
with several features that can impose difficulties. The initial
modeling necessary for designing an adaptive trial design is
rigorous and time consuming, outcome data must be collected
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rapidly, necessitating cooperation from trial sites, and, lastly, the
overall sample size with a large number of treatment arms will
be substantially greater than traditional phase IIB trials with only
2 to 3 active treatment arms. The stopping rule in ASTIN was
based on bounds of posterior probability. If the lower bound of
the credible interval around the estimated ED95 was more than a
predefined minimal efficacy threshold, a recommendation by the
Independent Data Monitoring Committee (IDMC) to stop the
study would have been made because efficacy would have been
demonstrated; a recommendation to stop the trial would have
been made if the upper bound of the credible interval was less
than a predefined threshold. The IDMC is critical in the conduct
of trials using this design or another type of adaptive design and
requires clinicians and statisticians to evaluate both safety-
related issues and the performance of the algorithm.
It is also important to demonstrate that adequate drug con-
centrations can be achieved in the target organ. It is uncommon
to have confirmation that a compound reaches the relevant brain
areas at therapeutic concentrations in either animals or humans.
Hence, studies should be performed to demonstrate that ade-
quate target tissue levels can be achieved in both animal models
and humans by direct cerebrospinal fluid or brain sampling. For
some compounds, MRI or positron-emission computed tomog-
raphy might provide useful information about central nervous
system drug penetration and tissue levels.
Broad entry criteria should be used in phase IIA safety studies
to evaluate unexpected risk at the extremes of age, comorbid
conditions, and stroke severity. In subsequent phase IIB studies,
more focused approaches with narrower entry criteria may
reasonably be used. Narrowing selection criteria in phase IIB to
target patients more likely to respond based on clinical and
imaging characteristics may optimize the chances of detecting a
biologically relevant drug effect.
Many reliable and validated outcome measures are available,
but there is a need for further refinement and improvement. The
Rankin score has been widely used but is suitable only when a
large difference in outcome among treatment groups is expect-
ed.7 The development and validation of surrogate outcome
measures, especially for phase IIB studies, may be helpful in
establishing the biological plausibility of a new therapeutic
approach and could be accomplished in a single trial with a split
sample and cross-validation approach. Putative surrogates
should have an established statistically documented relationship
to validated clinical outcome measures or may become validated
during the trial itself.8 The sensitivity and specificity of outcome
measures may be improved by the following:
1. Reducing the variability of assessment by, for example,
using a central assessment by a single person or panel or
by standardized investigator training.
2. Improving precision and reducing respondent variability
for assessing clinical outcome measures through comput-
erized adaptive testing. One strategy to use is Item Re-
sponse Theory statistical methodologies to create large
item pools capable of precise measurement, from which
only a small number of items are used to assess individual
subjects. Computerized adaptive testing can be used to
present only the most relevant items to the individual based
on his or her ability level and store the responses for
aggregate analysis.
3. Using more hypothesis-specific outcome measures. For
example, if a clinical trial is directed toward improving
mobility, outcome measures should be focused on gait
rather than on more general parameters that may dilute the
gait component. Using a combination of clinical and
imaging measures could be more sensitive than either
approach alone.
Similar recommendations apply to phase III trials, particu-
larly the need to develop more sensitive and specific outcome
measures. Sharing datasets by placing trial results in the
public domain in databases such as Virtual International
Stroke Trials Archive (VISTA) and MR STROKE would be
helpful in advancing the development and testing of new
outcome measures.
Although limitations in physical function following stroke
have a major impact on quality of life and contribute to the
economic burden of the disease,9,10 commonly used measure-
ment instruments are not sensitive across the entire continuum of
stroke severity.11–13 The most frequently used measure of stroke-
related physical disability is the Barthel index.14 Ceiling effects
limit its sensitivity to change because patients with the highest
score can, nevertheless, have substantial disabilities.15,16 The
physical domain of the Short Form 36 (SF-36) has also been
used to measure physical function after stroke.17,18 In contrast to
the Barthel index, the SF-36 has floor effects in which patients
with the lowest score may have further clinical deterioration.
Although different instruments could be used for patients at
different levels of severity, there are benefits to having a single
instrument. The Stroke Impact Scale (SIS) is a comprehensive
and psychometrically robust stroke-specific outcome measure
that was developed to extend the range of function measured by
the Barthel index and the physical domain of the SF-36.19,20 The
SIS was developed from the perspective of patients, caregivers,
and health professionals with stroke expertise and includes items
measuring 8 domains (strength, hand function, activities of daily
living and instrumental activities of daily living, mobility,
communication, emotion, memory and thinking, and participa-
tion). In addition to the full version of the SIS, an abbreviated
version that focuses on the physical domain has been devel-
oped.12 This shorter version, the SIS-16, is specifically designed
to better capture the broad range of poststroke physical limita-
tions. As such, it may be useful in monitoring improvement in
function over time in this population.
The debate concerning the advantages and disadvantages of
large megatrials versus smaller focused phase III trials should be
guided by the principles that sample sizes in trials are determined
by the study hypothesis and the expected effect size of the
intervention.21 For example, a trial for a neuroprotective agent
with a purported action restricted to white matter, a large
expected benefit (eg, 10%), and where the sample might
consist of stroke patients with discrete lacunar syndromes
demonstrated by imaging an appropriately powered trial might
requires a relatively small sample size. Another example would
be thrombolytic or device recanalization of a specific vessel,
such as the middle cerebral or basilar arteries. In such homoge-
neous stroke populations, an appropriately powered trial might
also involve a relatively small sample size because a greater
absolute treatment effect is possible in such reperfusion stud-
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ies.22 Although focused trials are useful for proof of concept,
they may not be broadly generalizable. Conversely, a mechanis-
tically heterogeneous patient population testing an intervention
with a small absolute expected benefit would require a large
sample size with outcomes measured by a relatively crude
measure. However, investigators conducting previous neuropro-
tection trials expected absolute benefits that were likely too
optimistic. This has likely resulted in “large,” but still under-
powered, trials.23 For example, realistic absolute effect sizes for
a neuroprotection drug should be 5% (range 2% to 8%) that
would require substantially larger sample sizes (4000 patients)
than previous trials. To control expense and patient and inves-
tigator fatigue, sample sizes need to be as small as possible to
test the hypothesis. Suggestions to accomplish this goal are
outlined in Table 1.
Several other issues related to outcome assessment should be
considered. Dependence on a single outcome measure may
obscure a beneficial treatment effect, especially in a heteroge-
neous population. The use of a global test statistic to incorporate
data from several measures is attractive and was used success-
fully in the National Institute of Neurological Disorders and
Stroke recombinant tissue plasminogen activator trial (NINDS
rt-PA). If a global test statistic of multiple end points is used, all
of them must be prespecified and those specified used in the
analysis. Heterogeneity among patients in terms of age, severity,
and pathophysiology contributes to wide variability outcome. In
the absence of highly restrictive selection criteria, a single
threshold to determine success may be inappropriate. A “re-
sponder” analysis adjusted to baseline severity and other factors
may be preferable. In its simplest form, a responder analysis
stratifies patients at randomization into groups according to
initial severity, predefines a different outcome measure indica-
tive of a positive effect for each stratum, and presumes that all of
the strata will be incorporated into the data analysis. For
example, the Abciximab in Emergent Stroke Treatment Trial
(AbESTT) assigned strata of National Institutes of Health Stroke
Scale Score (NIHSS) of 4 to 7, 8 to 14, and 15 and specified
thresholds for success based on the modified Rankin Scale of 0,
1, and 2, respectively.24 More complicated approaches
combine 2 baseline variables such as age and severity. For
example, among patients with moderate initial stroke severity,
older patients may be judged against a higher modified Rankin
Scale outcome than younger patients; a young patient with a low
NIHSS or an elderly patient with high NIHSS may be judged
ineligible for a trial, although other patients with similar stroke
severity remain eligible.25 Assessing improvement across the
entire range of an outcome scale, rather than losing outcome
information by dichotomization or trichotomization, is another
innovative approach to improving the sensitivity of trial end
points and is the preferred approach to clinical trial design.
When it is expected that the study intervention is likely to yield
clinical benefits across all levels of stroke severity, the use of all
of the data within a categorical scale will improve study power.26
This potentially more sensitive approach is being used in the
Field Administration of Stroke Therapy—Magnesium (FAST-
MAG) trial.27 The issue of trial expense is important for
sponsors and investigators. The majority of trial costs are
incurred in patient recruitment and monitoring. Suggested ap-
proaches for reducing cost are outlined in Table 2. By adopting
flexible and innovative approaches, the efficiency of transla-
tional research in acute stroke trials can be maximized.28
Enhancing Government, Industry, and
Academic Cooperation in Acute Stroke
Drug/Device Development
Successful clinical trials depend on excellent collaboration
and cooperation between government regulatory bodies such
as the US Food and Drug Administration (FDA), industry, the
trial leadership, and the individual study sites.29 Stroke
studies that include combinations of therapies (drug–drug,
drug–device, etc) will also involve multiple interested par-
ties. Given this reality, it is important to examine current
barriers, as well as suggested solutions, for the development
of organized stroke trial networks to facilitate study design
and implementation.
Studies with multiple stakeholders present unique challenges
and communication can be particularly complex. Many of the
communication problems may manifest themselves at study sites
where employees of 1 or more companies, coordinating center
personnel, and government representatives can all potentially
interact with local administrative and clinical personnel. To
minimize these local issues, experienced leadership from expe-
rienced study physicians and the overall study coordinator is
necessary.
The funding source has implications for investigators. Advan-
tages of NIH-sponsored clinical trials include greater investiga-
tor control of study design and conduct, a perception of objec-
tivity by peers, prestige for academic centers, and relatively
consistent long-term financial support for study cores. However,
the NIH peer-review process can take several years from idea
generation to awarding of funding. Pharmaceutical-sponsored
trials can begin more quickly but often entail less investigator
control. When studies combine NIH funding with industry-
sponsored activities (device, drug, or other), the administration
of the study becomes more complex, although this merger could
combine advantages from each type of sponsorship.
There are several important issues to consider related to
ethical review boards, which can be centralized, community or
TABLE 1. Potential Approaches to Reduce Sample Sizes in
Phase III Stroke Trials
1. More sensitive outcome measures.
2. Reducing variability of outcome assessment.
3. Developing new methods of analysis of outcome measures (see below).
4. Developing trial recruitment techniques to shorten time windows to
increase likely absolute benefit, for example, ambulance-based therapies
such as in the FAST-MAG trial.
TABLE 2. Approaches to Reducing Costs for Stroke Trials
1. Enhancing techniques to simplify recruitment and monitoring.
2. Maximizing productivity of individual centers and, thus, reduce the
spread of monitoring costs across a larger number of centers.
3. Developing better relationships between study phases; for example,
phase IIB studies may be rolled into phase III studies.
4. Using novel trial design approaches such as the adaptive design and
imaging-guided patient selection.
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institutionally based (ie, institutional review boards [IRBs]). One
important topic of concern for IRBs is indemnification that can
be particularly complex if a study involves multiple sponsors. If
a study involves both drugs and a device produced by different
sponsors, the device company may provide indemnification
related to device failure, and the pharmaceutical company may
indemnify only issues related to manufacturing defects or side
effects of the study drug. For NIH-sponsored trails, the NIH
cannot provide direct indemnification. As a result, local hospitals
and treating physicians may be left with significant medicolegal
risk and be reluctant to participate in trials. The indemnified
legal entity (eg, universities versus hospitals) may not be clear.
Early agreement by the sponsoring parties can help facilitate
dialogue with local IRBs and resolve some of these issues.
A second major contractual issue is the assignment of intel-
lectual property rights. Industry sponsors and lead investigators
need to agree on intellectual property issues before trial sites are
contacted. The most contentious issues often develop between
academic institutions and the device or pharmaceutical sponsors.
Negotiations around issues of intellectual property require
knowledgeable clinicians and clinical researchers to help resolve
institution–industry conflicts.
Despite the completion of more than 129 phase II and 60
phase III stroke trials, few effective treatments for stroke have
been identified.30,31 There is an urgent need for rapid and
efficient completion of additional trials of promising therapies.
Progress in developing effective stroke therapies has been
hampered by the lack of a large stroke clinical trial network in
the United States. Efforts including site identification, hiring
research personnel, developing case report forms, and develop-
ing data management systems often need to be redone for each
new trial. Recreating this complex infrastructure is inefficient
and costly. A more effective approach to facilitate rapid imple-
mentation and completion of clinical trials could be to develop a
nonprofit, academic, stroke clinical trial network or consortium
in the United States (that could potentially be expanded interna-
tionally). The primary mission of the network would be to
efficiently execute high-quality stroke clinical trials.
A stroke clinical trial network could offer a number of
important advantages for both industry- and investigator-
initiated trials. By maintaining an ongoing infrastructure, sup-
ported by a steady stream of projects, clinical trials could be
performed more rapidly and efficiently and at a lower cost. A
steering committee could identify the most scientifically sound
and promising studies and help ensure that trial design and
sample size are appropriate. An established network could
increase the likelihood that the participating sites and investiga-
tors have the necessary expertise, patient volume, and experi-
ence to successfully conduct the proposed trials. The network
approach could provide the stroke community with an opportu-
nity for education and training, facilitate rapid dissemination of
successful therapies into the community, and provide several
other advantages as outlined in Table 3.
Regulatory Considerations
The approval of acute stroke therapies requires adequate
safety and efficacy data that meet the current regulatory
standards.32 The FDA has recognized that stroke is a serious
and life-threatening condition, making it eligible for the
fast-track approval process. However, because tissue plas-
minogen activator (tPA) remains the only approved drug for
acute ischemic stroke, there is limited experience with the
regulatory process in this therapeutic area. Lessons and
examples regarding the regulatory process from other neuro-
logical and non-neurological serious and life-threatening
disorders can be extrapolated to acute stroke. Four broad
topics concerning the regulatory process for acute stroke
therapies were discussed: pre–phase III data, clinical trial
outcomes, novel approaches to regulatory approval, and
multiple therapies.
Much of the information and opinions regarding pre–phase III
data generation were reviewed in the STAIR-II report.2 Several
issues that are relevant for the regulatory process need amplifi-
cation and discussion. The importance of a dose-escalation study
before phase III is apparent, as the phase II study would provide
valuable safety information and could provide confirmatory
evidence of efficacy. Although the traditional approach to
determine a maximally tolerated dose is conducting phase II
studies, this may not be necessary in all situations, particularly if
a validated surrogate measure or clinical outcome measure
detected a biologically relevant effect at a dose less than the
maximally tolerated one.
The difficulties in detecting a clinical “signal” of efficacy are
apparent from previous phase II acute stroke studies.30 However,
there are several potential ways to try to increase the chances of
detecting a valid signal in phase II acute stroke studies. One
mechanism would be to enrich the population entered into a
phase II trial with those individuals most likely to respond, for
example, by only including subjects having a certain stroke
subtype or level of severity, strokes restricted to 1 vascular
territory, or patients with imaging study results that suggest the
presence of an ischemic penumbra, the presumed target of acute
stroke therapy.33 Also, assessing outcome measures at several
hours or days in phase II may also be easier and certainly more
economical than the traditional 90-day outcome time point. As
discussed, clinical outcome measures evaluating different do-
mains such as stroke severity, disability, cognitive status, or
quality of life might also be used to detect a signal in 1 of these
domains before proceeding to phase III.
Surrogate outcome measures for acute stroke trials may be
useful, but remain to be fully validated, in relationship to
accepted clinical outcomes. Biomarkers reflecting disease activ-
ity are currently available for use in phase II acute stroke studies
to provide evidence of drug activity on potentially relevant
targets related to this disorder.34 Preclinically, acute stroke
therapies are designed to reduce ultimate infarct size with the
assumption that clinical and functional outcome will be im-
proved on average if ischemic lesion size is smaller. Thrombo-
TABLE 3. Other Potential Benefits of Trial Consortia
1. Enhancing the efficiency of member centers for performing trials.
2. Enabling centers to more easily perform multiple, simultaneous trials.
3. Having a steering committee to provide expert leadership and opinions
about the scientific validity of proposed trials.
4. Providing additional opportunities for investigator education and training.
5. Providing the opportunity to perform trials related to relatively uncommon
clinical conditions, eg, carotid dissection or venous thrombosis.
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lytic agents are presumed to achieve this effect by early initiation
of nourishing reperfusion and reducing infarct size, whereas
neuroprotective agents are presumed to reduce infarct size by
interfering with aspects of the cellular cascade of tissue injury.33
A potentially relevant biomarker for a thrombolytic agent would
be vascular recanalization or an enhancement of reperfusion
within the initial few hours after stroke onset. This type of
biomarker approach was used in the initial tPA studies in acute
myocardial infarction. A recanalization/reperfusion effect in
acute ischemic stroke patients could be measured by imaging
modalities including traditional catheter-based angiography, CT
angiography, magnetic resonance angiography, perfusion CT,
perfusion MRI, or ultrasonography. A combination of these
modalities could also be used, as several of them provide
complementary information. A recent phase II study with the
novel thrombolytic desmoteplase suggested that the combination
of magnetic resonance angiography and perfusion MRI can
provide useful information concerning reperfusion efficacy.35
For both thrombolytics and neuroprotective drugs, the effect of
treatment on ischemic lesion evolution or salvage of the
imaging-identified penumbra may be potentially relevant bi-
omarkers. MRI is most applicable for this approach by using
diffusion MRI pretreatment and T2-weighted or fluid-attenuated
inversion recovery imaging at the more chronic time point. One
preliminary study suggests that a lack of lesion growth over time
is associated with much higher likelihood of reduced clinical
severity.36 Demonstrating recanalization/reperfusion effects with
thrombolytics and inhibition of lesion growth with thrombolytics
or neuroprotectants would be useful in confirming relevant
effects on stroke pathophysiology and potentially provide causal
confirmation of drug activity.33 Not only might this information
be useful in reassuring sponsors that the candidate agent has
relevant activity in the target population, but the information
could also be used to provide confirmatory evidence required for
approval by the FDA based on the FDA Modernization Act of
1997.37 This assumes that treatment with the agent also leads to
a statistically significant beneficial effect in an adequately
powered, well-conducted phase III study with a clinically rele-
vant outcome. A report discussing these FDA Modernization
Act provisions has emphasized that the confirmatory evidence
must be scientifically sound.38 Adequate confirmatory evidence,
given that the mechanism of the drug is known, would establish
some measure of biological activity, ie, would establish that the
drug elicits the expected pharmacological action. In this regard,
a dose-response pilot study demonstrating a dose-related effect
on relevant biologic activity such as recanalization/reperfusion
or ischemic lesion growth would be strong evidence that
confirms an empirical, phase III randomized clinical trial with a
clinical end point.
Finally, in pre–phase III studies, the issue of including
patients with hemorrhage and stroke mimics should be consid-
ered. If hemorrhage patients and stroke mimics are to be
included in the marketing package, then such patients should be
included in the investigational design to ensure safety in this
patient population.
Because of the poor record of neuroprotective monotherapy
for acute ischemic stroke, combination therapies are the most
likely way to markedly enhance the potential for improving
outcome.2 For combination drug trials in acute ischemic stroke,
it would appear, based on current FDA recommendations, that it
is necessary to study each component individually along with the
combination, unless there was evidence that 1 of the components
by itself would be harmful. Studying each drug in the combina-
tion as monotherapy is necessary to confirm that all or most of
the benefit of the combination is not derived from 1 component
of the combination or that side effects are not entirely related to
1 drug in the combination. A factorial design would be the most
efficient approach to a combination therapy trial. FDA attitudes
on this issue are changing, as such combinational approaches are
used in other therapeutic areas. In particular, if there is reason-
able preclinical evidence that the individual components of the
combination are either inactive or have a low likelihood of
efficacy, then the FDA should be approached to help in under-
standing how such a combination might be most efficiently
tested.
A second approach to multiple therapy trials is adding a new
therapy onto an existing therapy such as tPA. For 3-hour
time-window studies that include subjects who qualify for IV
tPA, it is no longer acceptable to have a placebo arm in countries
where tPA is currently approved. Therefore, a novel drug given
in combination with tPA would have to be compared with tPA
alone. In subjects who do not qualify for tPA, the drug would be
compared with placebo. A stratified randomization scheme
would be appropriate in this situation. Despite the use of
intraarterial therapy up to 6 hours after stroke onset, there is no
approved therapy 3 hours. Therefore, a placebo arm is still
ethically justified in studies beyond 3 hours.
Conclusions
The development and approval of additional pharmacological
therapies for acute ischemic stroke remains complex and
challenging. Efforts to develop additional stroke treatments
will require adapting and improving clinical trial design and
implementation, increasing cooperation among the relevant
participating parties and being cognizant of regulatory re-
quirements and changes in the regulatory process. The
traditional approach to acute stroke clinical trial design has
been problematic at multiple levels. Research questions must
be prioritized. Novel approaches to trial design are needed.
The stroke research community must address slow recruit-
ment into clinical trials and multiple competing trials. Surro-
gate markers, especially imaging, must be validated and
combination therapies developed. Finally, licensing agencies
should work with the stroke community and must recognize
the unique challenges of acute stroke trial design that may
warrant a different regulatory approach from other disease
processes. The requirements of device trials are now impact-
ing on trial methodology and will be the topic of a future
STAIR conference.
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